Teleflex (TFX) Q3 2026 Earnings: A Tariff Refund Powers a 39% EPS Beat

Teleflex posted adjusted diluted EPS of $2.63 for the third quarter of 2026, well above the $1.89 consensus estimate. The primary driver was a $16.5 million refund of IEEPA tariffs, which became available after the Supreme Court invalidated those levies. That single item added 290 basis points to adjusted gross margin, lifting it to 66.8% from 62.3% a year earlier, and helped push adjusted operating margin to 25.0% from 22.0%.

Revenue came in at $567.8 million, edging 0.43% above the $565.4 million estimate. On a reported basis, however, revenue fell 37.8% year over year, a figure that reflects the August 3 close of the company's OEM divestiture to Montagu and Kohlberg for $1.5 billion rather than any weakness in the underlying business. Among Teleflex's three remaining global business units, Vascular grew 4.7% and Surgical rose 4.2%, while Interventional returned to modest growth after a period of contraction.

CEO Jason Weidman emphasized that the earnings performance held up even setting aside the tariff windfall. In his words: "We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds." He also pointed to the reorganization into three global business units as a structural milestone, describing it as simplifying the company's operating model.

On the strength of the quarter, management raised its full-year adjusted EPS guidance to $7.50 to $7.75, while maintaining its pro forma adjusted constant-currency revenue growth outlook of 3.5% to 4.5%. The updated guidance assumes roughly 20% adjusted operating margin for the full year and incorporates the $16.5 million tariff refund. It does not include any benefit from the pending sale of the Acute Care and Interventional Urology businesses, which Teleflex is still targeting to close by year-end, subject to regulatory approval.

The pipeline also offers a longer-term watch item. Teleflex's Freesolve resorbable magnesium scaffold holds FDA Breakthrough Device Designation, enrollment in the BIOMAG-II trial against a drug-eluting stent wrapped up ahead of schedule, and one-year data are expected in late 2027. Additionally, EZPLAZ, the first FDA-licensed freeze-dried plasma, was approved in late July 2026, with the U.S. government and military identified as the initial priority market for what management sees as at least a $200 million long-term U.S. opportunity.